Literature DB >> 14629829

Sterically stabilized etoposide liposomes: evaluation of antimetastatic activity and its potentiation by combination with sterically stabilized pentoxifylline liposomes in mice.

Vinayak P Sant1, M S Nagarsenker, S G Anand Rao, Rajiv P Gude.   

Abstract

Cytotoxic activity of chemotherapeutic agents can be enhanced by site-specific delivery or by combination with other less toxic agents. In the present study, enhancement in the antimetastatic activity of etoposide (ETP) by encapsulation in sterically stabilized liposomes was evaluated in the murine experimental B16F10 melanoma model. Further, potentiation of its antimetastatic activity by combination with pentoxifylline (PTX) solution or sterically stabilized PTX liposomes was evaluated in the same animal model. Upon intravenous administration, ETP solution and ETP liposomes inhibited pulmonary tumor nodule formation in a dose-dependent manner. Encapsulation of ETP in liposomes resulted in significant enhancement in its antimetastatic activity at doses of 0.5 mg/kg and 0.75 mg/kg as compared to ETP solution at similar doses. In combination therapy, the effect of sequence of administration of the drugs, ETP and PTX, was evaluated. Enhancement of antimetastatic activity of ETP solution when used in combination with PTX solution was effected by the sequence in which the solutions were administered. However, a combination of ETP liposomes and PTX liposomes led to potentiation of antimetastatic activity in a sequence-independent manner. The results indicate that antimetastatic activity of ETP is significantly enhanced by encapsulation in liposomes. Administration of ETP liposomes with PTX liposomes further potentiated the activity, suggesting the usefulness of this combination in clinical practice for reducing the dose-limiting toxic effects of ETP.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14629829     DOI: 10.1089/108497803770418355

Source DB:  PubMed          Journal:  Cancer Biother Radiopharm        ISSN: 1084-9785            Impact factor:   3.099


  2 in total

1.  Inhibition of tumor angiogenesis by oral etoposide.

Authors:  Dipak Panigrahy; Arja Kaipainen; Catherine E Butterfield; Deviney M Chaponis; Andrea M Laforme; Judah Folkman; Mark W Kieran
Journal:  Exp Ther Med       Date:  2010-07-21       Impact factor: 2.447

Review 2.  Pharmaceutical and pharmacological approaches for bioavailability enhancement of etoposide.

Authors:  Ishtiyaq Ahmad Najar; Rakesh Kamal Johri
Journal:  J Biosci       Date:  2014-03       Impact factor: 1.826

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.